Dyskinesia (Central Nervous System) - Drugs In Development, 2021

July 2021 | 294 pages | ID: D76A1793D32DEN
Global Markets Direct

Abstracts

Dyskinesia (Central Nervous System) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Drugs In Development, 2021, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 15, 8, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Dyskinesia - Overview
Dyskinesia - Therapeutics Development
Dyskinesia - Therapeutics Assessment
Dyskinesia - Companies Involved in Therapeutics Development
Dyskinesia - Drug Profiles
Dyskinesia - Dormant Projects
Dyskinesia - Discontinued Products
Dyskinesia - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Dyskinesia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Dyskinesia - Pipeline by Addex Therapeutics Ltd, 2021
Dyskinesia - Pipeline by AEON Biopharma Inc, 2021
Dyskinesia - Pipeline by AfaSci Inc, 2021
Dyskinesia - Pipeline by Amarantus Bioscience Holdings Inc, 2021
Dyskinesia - Pipeline by Astraea Therapeutics LLC, 2021
Dyskinesia - Pipeline by Bod Australia Ltd, 2021
Dyskinesia - Pipeline by Cannabis Science Inc, 2021
Dyskinesia - Pipeline by Celon Pharma SA, 2021
Dyskinesia - Pipeline by Cerevance Inc, 2021
Dyskinesia - Pipeline by Cerevel Therapeutics Holdings Inc, 2021
Dyskinesia - Pipeline by Contera Pharma ApS, 2021
Dyskinesia - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Dyskinesia - Pipeline by DanPET AB, 2021
Dyskinesia - Pipeline by Domain Therapeutics SA, 2021
Dyskinesia - Pipeline by EpiVax Inc, 2021
Dyskinesia - Pipeline by GraySpace Therapeutics Inc, 2021
Dyskinesia - Pipeline by Hua Medicine Shanghai Ltd, 2021
Dyskinesia - Pipeline by Ipsen SA, 2021
Dyskinesia - Pipeline by IRLAB Therapeutics AB, 2021
Dyskinesia - Pipeline by Jazz Pharmaceuticals Plc, 2021
Dyskinesia - Pipeline by Junaxo Inc, 2021
Dyskinesia - Pipeline by MapLight therapeutics Inc, 2021
Dyskinesia - Pipeline by Medytox Inc, 2021
Dyskinesia - Pipeline by Melior Pharmaceuticals II LLC, 2021
Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, 2021
Dyskinesia - Pipeline by MitoDys Therapeutics Ltd, 2021
Dyskinesia - Pipeline by Molomics Biotech SL, 2021
Dyskinesia - Pipeline by Motac Neuroscience Ltd, 2021
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, 2021
Dyskinesia - Pipeline by Neurocea Pharmaceuticals, 2021
Dyskinesia - Pipeline by Neurocrine Biosciences Inc, 2021
Dyskinesia - Pipeline by Neurolixis Inc, 2021
Dyskinesia - Pipeline by Newron Pharmaceuticals SpA, 2021
Dyskinesia - Pipeline by Nissan Chemical Corp, 2021
Dyskinesia - Pipeline by Novartis AG, 2021
Dyskinesia - Pipeline by OB Pharmaceuticals, 2021
Dyskinesia - Pipeline by Peptron Inc, 2021
Dyskinesia - Pipeline by PharmaTher Holdings Ltd, 2021
Dyskinesia - Pipeline by PolyCore Therapeutics LLC, 2021
Dyskinesia - Pipeline by Praxis Precision Medicines Inc, 2021
Dyskinesia - Pipeline by Revance Therapeutics Inc, 2021
Dyskinesia - Pipeline by Sage Therapeutics Inc, 2021
Dyskinesia - Pipeline by SalubRx Therapeutics Inc, 2021
Dyskinesia - Pipeline by Shionogi & Co Ltd, 2021
Dyskinesia - Pipeline by Sinopia Biosciences Inc, 2021
Dyskinesia - Pipeline by SOM Biotech SL, 2021
Dyskinesia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
Dyskinesia - Pipeline by Tempero Bio, 2021
Dyskinesia - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
Dyskinesia - Pipeline by Trevi Therapeutics Inc, 2021
Dyskinesia - Pipeline by Ultragenyx Pharmaceutical Inc, 2021
Dyskinesia - Pipeline by VistaGen Therapeutics Inc, 2021
Dyskinesia - Dormant Projects, 2021
Dyskinesia - Dormant Projects, 2021 (Contd..1)
Dyskinesia - Dormant Projects, 2021 (Contd..2)
Dyskinesia - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Dyskinesia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021